Cancer immunotherapy

#Cancer immunotherapy #Cancer research #Cancer Research Month #Diagnostics #Immunotherapy #Oncology #Precision medicine

National Cancer Research Month: Celebrating drug discovery innovation

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. As the US National Cancer Research Month draws to a close, we asked experts from across the industry “What do… Read More

#Cancer Research #Exclusive Content

Bone cancer
#Bone cancer #Cancer immunotherapy #Childhood cancer #CureSearch

CureSearch to fund new study for aggressive paediatric bone cancer 

CureSearch for Children’s Cancer, a national non-profit working to end childhood cancer by driving targeted and innovative research in an accelerated time frame, will fund a novel project aimed at developing therapies for osteosarcoma, an aggressive form of bone cancer.   Kristen VanHeyst, DO of University Hospitals… Read More

#News

T cell attacking cancer cell
#Cancer immunotherapy #Cancer research #Cell therapy #Immunotherapy #Oncology #Personalised medicine #Webinar

The future of cancer immunotherapy: exclusive webinar

Hosted by DDW and supported by BPS BioScience and AcroBiosystems, ‘Cancer immunotherapy – where will the future opportunities be?’ will be free to attend on May 10 at 8AM PST | 11AM EST | 4PM BST | 5PM CET.   Join this free webinar to… Read More

Webinar date:
Brought to you by BPS BioScience and AcroBiosystems
#News

T cells
#Cancer immunotherapy #Cancer research #Cell therapy #Immunotherapy #Oncology #Personalised medicine #Webinar

Learn about cancer immunotherapy in this webinar

Hosted by DDW and supported by BPS BioScience and AcroBiosystems, ‘Cancer immunotherapy – where will the future opportunities be?’ will be free to attend on May 10 at 8AM PST | 11AM EST | 4PM BST | 5PM CET.   Join this free webinar to… Read More

Webinar date:
Brought to you by BPS BioScience and AcroBiosystems
#News

Cancer immunotherapy
#Cancer immunotherapy #Cancer research #Cell therapy #Immunotherapy #Oncology #Personalised medicine #Webinar

Webinar on the future opportunities for cancer immunotherapy

Hosted by DDW and supported by BPS BioScience and ACROBiosystems, ‘Cancer immunotherapy – where will the future opportunities be?’ will be free to attend on May 10 at 8AM PST | 11AM EST | 4PM BST | 5PM CET.   Join this free webinar to… Read More

Webinar date:
Brought to you by BPS BioScience and AcroBiosystems
#News

Cancer immunotherapy
#Cancer immunotherapy #Cancer research #Cell therapy #Immunotherapy #Oncology #Personalised medicine

Cancer immunotherapy – where will the future opportunities be?

Watch this free webinar to learn about the biggest opportunities for the future of cancer immunotherapy.   In this free webinar, you will hear from immunologist Dr Frédéric Triebel, CSO and CMO of Immutep, two experts from DeciBio: Dr Carl Schoellhammer, Principal, and Dr Joe Daccache, Senior Life… Read More

Webinar date:
Brought to you by BPS BioScience and AcroBiosystems
#Webinars

#AACR #AACR 2023 #Awards #Cancer immunotherapy #Cancer research #Immunology / Virology & Vaccines

Tuesday 18 April at AACR Annual Meeting 2023

DDW’s Megan Thomas rounds up highlights from Tuesday 17 April at AACR 2023, from AI and mathematical oncology to winners of the AACR James S Ewing-Thelma B Dunn Award for Outstanding Achievement in Pathology in Cancer Research. Clinical announcements Promising results for olaparib plus ceralasertib Today, results from the Phase… Read More

#News

#AACR #AACR 2023 #Awards #Cancer immunotherapy #Cancer research #Immunology / Virology & Vaccines

Monday 17 April at AACR Annual Meeting 2023

DDW’s Megan Thomas rounds up highlights from Monday 16 April at AACR 2023, from promising trial results for colorectal cancer patients to updates on Biden’s Cancer Moonshot initiative. Clinical announcements  Data on colorectal cancer patients with African ancestry Today, data presented at the AACR Annual Meeting showed that genomic… Read More

#News

#AACR #AACR 2023 #Awards #Cancer immunotherapy #Cancer research #Immunology / Virology & Vaccines #mRNA

Sunday 16 April at AACR Annual Meeting 2023

DDW’s Megan Thomas rounds up highlights from Sunday 16 April at AACR 2023, from promising trial results for a personalised mRNA-based cancer vaccine to winners of lifetime achievement awards. Opening plenary session Sunday’s opening plenary session borrowed its name from the Annual Meeting theme, “Advancing the Frontiers of Cancer Science… Read More

#News

#AACR 2023 #Cancer #Cancer immunotherapy #Cancer research #Oncology #Therapeutics

Eight announcements to expect at AACR 2023   

The American Association for Cancer Research (AACR) Annual Meeting is taking place at the Orange County Convention Center in Orlando, Florida from April 14-19, 2023. As the theme, Advancing the Frontiers of Cancer Science and Medicine, suggests, a number of announcements, results and presentations will take place… Read More

#News

#Cancer immunotherapy #Immunology / Virology & Vaccines #Moderna #mRNA #mRNA-based vaccines #Tumour biology

Vaccine for the ‘previously undruggable’ just a decade away 

In an exclusive interview with The Guardian, Moderna said that cancer and heart disease vaccines would be ready by 20301. The pharmaceutical firm also provided promising updates on mRNA-4157/V940, which targets different tumour types, at Moderna’s Vaccines Day on 24 March 20232.   The… Read More

#News

#Autoimmune disease #Breast cancer #Cancer immunotherapy #Clinical trials #Immunotherapy #LAG-3

Phase II/III trial to assess LAG-3 immunotherapy in breast cancer 

Immutep, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, has initiated AIPAC-003 (Active Immunotherapy, Eftilagimod Alpha, and Paclitaxel), an integrated Phase II/III trial to evaluate eftilagimod alpha (efti) in combination with paclitaxel for the treatment of metastatic HER2-neg/low breast cancer (MBC).  … Read More

#News

CAR-T cell attacking cancer
#Cancer immunotherapy #Cancer research #CAR-T #Cell therapy #Immunotherapy #Karolinska Institutet #Oncology

CAR-T cell therapy holds promise for ovarian cancer

CAR-T cell therapy is effective in mice with ovarian cancer, according to a study published in The Journal for ImmunoTherapy of Cancer.   The study authors, who work at Karolinska Institutet, hope that the discovery will pave the way for a clinical trial… Read More

#Cancer Research #News #Trending News

#Assay development optimisation & technology #Cancer immunotherapy #Cancer research #Immuno-oncology #Immunotherapy #Oncology

The evolution of assays for immuno-oncology research

Listen to this article on the DDW Podcast: By Dr Shailendra Singh, founder and CEO of Cellomatics Biosciences. Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. The number of new cases recorded between 2016 and 2018 was 375,400, with 167,142 deaths… Read More

#Cancer Research #Exclusive Content

#Cancer immunotherapy #Cancer research #Immuno-oncology #Immunotherapy #Oncology #Phase III trial

Immunotherapy offers survival extension for brain tumour patients

Listen to this article on the DDW Podcast: Why data from a Phase III clinical trial offers promise for patients with a deadly form of brain cancer. A Phase III clinical trial has produced promising results for a cancer vaccine targeting patients with a new or recurrent glioblastoma.  The study, which… Read More

#Cancer Research #Exclusive Content

#Cancer immunotherapy #Cancer research #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies

Listen to the first DDW Highlights podcast for 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The drug discovery industry has hit the ground running in 2023 with… Read More

#News